Zheng Wang

Dr. Zheng Wang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
LLLin Li
Lin Li
LCLili Chen
Lili Chen
SYShaomin Yang
Shaomin Yang
YLYongjian Liu
Yongjian Liu
HLHanping Li
Hanping Li
JLJingyun Li
Jingyun Li
Recombination contributes substantially to the genetic diversity of HIV-1, and mosaic strains arise frequently, especially in populations in which multiple subtypes circulate. Yunnan, which borders the "Golden triangle" region of Southeast Asia in the south, was considered as the epicenter of China. B, CRF01_AE, CRF07_BC, and CRF08_BC are all currently involved in the HIV-1 epidemiology in the area, which suggested the possible emergence of a new recombination. This study presented a near full-length genomic analysis of a novel HIV-1 recombination involving B and C. Different from the reported CRF07_BC and CRF08_BC, the new recombination revealed more breakpoints. This is the first report of a novel recombination involving subtype B and C in Yunnan, China. More work is needed to determine the epidemiologic significance of the new recombination.

25 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
HYHu Yuanyuan
Hu Yuanyuan
SZSen Zou
Sen Zou
ZWZheng Wang
Zheng Wang
YLYing Liu
Ying Liu
LRLi Ren
Li Ren
KHKunxue Hong
Kunxue Hong
We sought to analyze the evolutionary characteristics and neutralization sensitivity of viruses in a human immunodeficiency virus type 1 (HIV-1) subtype B′ infected plasma donor with broadly neutralizing activity, which may provide information for new broadly neutralizing antibodies (bNAbs) isolation and immunogen design. A total of 83 full-length envelope genes were obtained by single-genome amplification (SGA) from the patient’s plasma at three consecutive time points (2005, 2006, and 2008) spanning four years. In addition, 28 Env-pseudotyped viruses were constructed and their neutralization sensitivity to autologous plasma and several representative bNAbs were measured. Phylogenetic analysis showed that these env sequences formed two evolutionary clusters (Cluster I and II). Cluster I viruses vanished in 2006 and then appeared as recombinants two years later. In Cluster II viruses, the V1 length and N-glycosylation sites increased over the four years of the study period. Most viruses were sensitive to concurrent and subsequent autologous plasma, and to bNAbs, including 10E8, PGT121, VRC01, and 12A21, but all viruses were resistant to PGT135. Overall, 90% of Cluster I viruses were resistant to 2G12, while 94% of Cluster II viruses were sensitive to 2G12. We confirmed that HIV-1 continued to evolve even in the presence of bNAbs, and two virus clusters in this donor adopted different escape mechanisms under the same humoral immune pressure.

1 September 2021 in Virus Research
Verified
Journal Article
Closed access
YHYuanyuan Hu
Yuanyuan Hu
DLDan Li
Dan Li
HFHongyang Fu
Hongyang Fu
YHYanling Hao
Yanling Hao
LRLi Ren
Li Ren
ZWZheng Wang
Zheng Wang

1 November 2024 in Journal of Infection
Verified
Journal Article
Open access
HLHuan Li
Huan Li
YFYi Feng
Yi Feng
YXYang Xu
Yang Xu
TLTang Li
Tang Li
QLQi Li
Qi Li
HXHui Xing
Hui Xing

27 January 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
CHCaiqin Hu
Caiqin Hu
DLDan Li
Dan Li
ZLZhanmou Liu
Zhanmou Liu
LRLi Ren
Li Ren
JSJunwei Su
Junwei Su
YSYiming Shao
Yiming Shao
Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research.

21 February 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
DLDan Li
Dan Li
CHCaiqin Hu
Caiqin Hu
JSJunwei Su
Junwei Su
SDShuo Du
Shuo Du
YZYing Zhang
Ying Zhang
YSYiming Shao
Yiming Shao
The ongoing emergence of evolving SARS-CoV-2 variants poses great threaten to the efficacy of authorized monoclonal antibody-based passive immunization or treatments. Developing potent broadly neutralizing antibodies (bNabs) against SARS-CoV-2 and elucidating their potential evolutionary pathways are essential for battling the coronavirus disease 2019 (COVID-19) pandemic. Broadly neutralizing antibodies were isolated using single cell sorting from three COVID-19 convalescents infected with prototype SARS-CoV-2 strain. Their neutralizing activity against diverse SARS-CoV-2 strains were tested in vitro and in vivo, respectively. The structures of antibody-antigen complexes were resolved using crystallization or Cryo-EM method. Antibodyomics analyses were performed using the non-bias deep sequencing results of BCR repertoires. We obtained a series of RBD-specific monoclonal antibodies with highly neutralizing potency against a variety of pseudotyped and live SARS-CoV-2 variants, including five global VOCs and some Omicron subtypes such as BA.1, BA.2, BA.4/5, BF.7, and XBB. 2YYQH9 and LQLD6HL antibody cocktail also displayed good therapeutic and prophylactic efficacy in an XBB.1.16 infected hamster animal model. Cryo-EM and crystal structural analyses revealed that broadly neutralizing antibodies directly blocked the binding of ACE2 by almost covering the entire receptor binding motif (RBM) and largely avoided mutated RBD residues in the VOCs, demonstrating their broad and potent neutralizing activity. In addition, antibodyomics assays indicate that the germline frequencies of RBD-specific antibodies increase after an inactivated vaccine immunization. Moreover, the CDR3 frequencies of Vκ/λ presenting high amino acid identity with the broadly neutralizing antibodies were higher than those of VH. These data suggest that current identified broadly neutralizing antibodies could serve as promising drug candidates for COVID-19 and can be used for reverse vaccine design against future pandemics.